Skip to main content

Table 3 Trialists’ understanding of core outcome sets (COS)

From: A survey of knowledge, perceptions and use of core outcome sets among clinical trialists

  Median Range IQR
COS are the minimum that should be measured for specific health or health care area 4 1–5 4
COS are the minimum that should be reported for specific health or health care area 4 1–5 4
All outcomes in the COS should be measured 4 1–5 2
Other outcomes can be measured in addition to outcomes in COS 5 2–5 1
COS can be used in research other than trials (e.g. evidence synthesis, observational studies) 5 3–5 1
COS are relevant to clinical audit and routine care 4 3–5 1
COS can involve input from relevant stakeholders 5 3–5 1
COS require consensus processes in development 5 2–5 1
Development of a COS involves multiple stages 5 4–5 0.75
Understanding of what COS are 4 2–5 1
Perceived importance of COS in clinical trials 3 2–3 1
  1. IQR interquartile range
  2. The last question is measured on a scale of 1 (not important) to 3 (very important); all other questions are measured using a scale from 1 (strongly disagree) to 5 (strongly agree); only participants who reported being familiar with COS (n = 40) responded to these questions